학술논문
Rechallenge with Anti-EGFR Therapy in Metastatic Colorectal Cancer (mCRC): Results from South Australia mCRC Registry.
Document Type
Academic Journal
Author
Chong LC; Department of Medical Oncology, The Queen Elizabeth Hospital, Adelaide, SA, Australia.; Hardingham JE; Department of Medical Oncology, The Queen Elizabeth Hospital, Adelaide, SA, Australia.; Adelaide Medical School, University of Adelaide, Adelaide, SA, Australia.; Townsend AR; Department of Medical Oncology, The Queen Elizabeth Hospital, Adelaide, SA, Australia.; Adelaide Medical School, University of Adelaide, Adelaide, SA, Australia.; Piantadosi C; Department of Surgery, Flinders Medical Centre, Bedford Park, SA, Australia.; Rico GT; Department of Medical Oncology, The Queen Elizabeth Hospital, Adelaide, SA, Australia.; Karapetis C; Department of Medical Oncology, Flinders Medical Centre and Flinders University, Adelaide, SA, Australia.; Padbury R; Department of Surgery, Flinders Medical Centre, Bedford Park, SA, Australia.; Maddern G; Department of Surgery, The Queen Elizabeth Hospital, Adelaide, SA, Australia.; Roy A; Department of Medical Oncology, Flinders Medical Centre and Flinders University, Adelaide, SA, Australia.; Price TJ; Department of Medical Oncology, The Queen Elizabeth Hospital, Adelaide, SA, Australia. Timothy.Price@sa.gov.au.; Adelaide Medical School, University of Adelaide, Adelaide, SA, Australia. Timothy.Price@sa.gov.au.; The Queen Elizabeth Hospital, TQEH Woodville Road, Woodville, SA, 5011, Australia. Timothy.Price@sa.gov.au.
Source
Publisher: Springer-Verlag France Country of Publication: France NLM ID: 101270595 Publication Model: Print Cited Medium: Internet ISSN: 1776-260X (Electronic) Linking ISSN: 17762596 NLM ISO Abbreviation: Target Oncol Subsets: MEDLINE
Subject
Language
English
Abstract
Background: Anti-epidermal growth factor receptor (EGFR) monoclonal antibodies (cetuximab or panitumumab) are today increasingly used in the first- or second-line setting for RAS wild-type metastatic colorectal cancer (CRC) patients. Following progression beyond third- or fourth-line therapy, some patients are unsuitable for further chemotherapy because of poor performance status or patient choice. However, a significant number of patients are still candidates for further therapy despite limited standard options being available. The role of rechallenge with anti-EGFR therapy, particularly in patients who had previously responded, is often considered, but there is limited evidence in the literature to support such a strategy.
Objective: This retrospective study aims to review the outcome of metastatic CRC patients who had anti-EGFR rechallenge.
Patients and Methods: Patients who had been rechallenged with anti-EGFR therapy were identified from the South Australian metastatic CRC database. Patient characteristics were recorded and tumor response was retrospectively assessed using Response Evaluation Criteria in Solid Tumors (RECIST). Kaplan-Meier analysis was used to assess progression free survival (PFS) for each rechallenge and overall survival (OS).
Results: Twenty-two patients were eligible for inclusion in this analysis. Disease control rate (stable disease and partial response) was 45.4% (ten patients) for patients who received rechallenge anti-EGFR. Seven patients received a second rechallenge and disease control rate was 28.6% (two patients). The median interval time between initial anti-EGFR therapy and rechallenge was 13.5 months. The median PFS after rechallenge 1 was 4.1 months and after rechallenge 2 was 3.5 months. The median OS was 7.7 months from date of rechallenge.
Conclusions: Anti-EGFR rechallenge provides clinical benefit in patients with RAS wild-type metastatic CRC.
Objective: This retrospective study aims to review the outcome of metastatic CRC patients who had anti-EGFR rechallenge.
Patients and Methods: Patients who had been rechallenged with anti-EGFR therapy were identified from the South Australian metastatic CRC database. Patient characteristics were recorded and tumor response was retrospectively assessed using Response Evaluation Criteria in Solid Tumors (RECIST). Kaplan-Meier analysis was used to assess progression free survival (PFS) for each rechallenge and overall survival (OS).
Results: Twenty-two patients were eligible for inclusion in this analysis. Disease control rate (stable disease and partial response) was 45.4% (ten patients) for patients who received rechallenge anti-EGFR. Seven patients received a second rechallenge and disease control rate was 28.6% (two patients). The median interval time between initial anti-EGFR therapy and rechallenge was 13.5 months. The median PFS after rechallenge 1 was 4.1 months and after rechallenge 2 was 3.5 months. The median OS was 7.7 months from date of rechallenge.
Conclusions: Anti-EGFR rechallenge provides clinical benefit in patients with RAS wild-type metastatic CRC.